Opinion|Videos|September 4, 2024
Navigating SG-related Diarrhea
Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please comment on your absolute neutrophil count cutoff for dose reductions and/or delay of sacituzumab govitecan (SG) therapy.
- How do you manage subsequent doses for patients who experienced febrile neutropenia with the previous cycle?
- How often do you see diarrhea (associated with SG) in your clinical practice? How does it compare to the rates reported in clinical trials (ASCENT, TROPiCS-02)?
- Are there risk factors that can predict those who are at higher risk for developing diarrhea?
- Are there any situations where you would consider testing for UGT1A1*28 homozygosity?
- Please comment on how you typically manage SG-related diarrhea.
- Are you utilizing prophylactic atropine or loperamide to prevent cholinergic syndrome prior to Cycle 1 of SG?
- Please comment on your management strategy for SG-related diarrhea (any similarities vs differences).
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5